IC
APLS

Ikarian Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Ikarian Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-325,600
Closed -$8.18M – 168
2025
Q4 		$8.18M Sell
325,600
-32,400
-9% -$760K 0.64% 46
2025
Q3 		$8.1M Buy
+358,000
New +$8.35M 0.82% 32
2024
Q4 		– Sell
-150,000
Closed -$4.33M – 175
2024
Q3 		$4.33M Buy
+150,000
New +$5.56M 0.6% 50
2024
Q1 		– Sell
-150,000
Closed -$8.98M – 140
2023
Q4 		$8.98M Buy
150,000
+147,635
+6,242% +$7.49M 0.84% 40
2023
Q3 		$9M Buy
+2,365
New +$104K 1.08% 29
2022
Q3 		– Sell
-123,200
Closed -$5.57M – 110
2022
Q2 		$5.57M Sell
123,200
-51,900
-30% -$2.37M 1.02% 33
2022
Q1 		$8.9M Sell
175,100
-24,900
-12% -$1.1M 1.17% 24
2021
Q4 		$9.46M Sell
200,000
-33,000
-14% -$1.3M 1.41% 20
2021
Q3 		$7.68M Sell
233,000
-67,000
-22% -$3.76M 0.54% 48
2021
Q2 		$19M Buy
+300,000
New +$15.5M 1.53% 12
2020
Q1 		– Sell
-240,300
Closed -$7.36M – 155
2019
Q4 		$7.36M Buy
+240,300
New +$6.65M 1.19% 26

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital's APLS Position: Q1 2026 in Review

Ikarian Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 71,747 shares — an estimated $1.8M sold.

Ikarian Capital first reported a position in APLS in Q4 2019 and held it in 15 quarters. The position peaked at $12.2M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Ikarian Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 71,747 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Ikarian Capital first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Ikarian Capital's Apellis Pharmaceuticals position peaked at $12.2M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.